Pioneering Next Generation Antibody Drug Conjugates (ADCs)

LATEST NEWS


April 15, 2025: ‘Radiance announces first patient dosing in Phase I Clinical Trial of its next generation ROR-1 targeted ADC for hematologic and solid malignancies‘GlobeNewswire


April 1, 2025: ‘Radiance announces FDA clearance of IND application for a Phase I Clinical Trial of RB-164™, an ROR-1 targeted ADC, for hematologic and solid malignancies‘GlobeNewswire

February 19, 2025: ‘Radiance rolls into ROR1 race, paying $15M for ADC rival to Merck’s frontrunner‘Fierce Biotech


February 19, 2025: ‘Radiance Biopharma Enters Exclusive License For ROR-1 Targeted Antibody Drug Conjugate‘ – GlobeNewswire



January 8, 2024: ‘Biocytogen enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma‘ – Businesswire